RT Journal Article
T1 Systemic treatment of renal cell cancer: A comprehensive review.
A1 Sánchez-Gastaldo, Amparo
A1 Kempf, Emmanuelle
A1 González Del Alba, Aránzazu
A1 Duran, Ignacio
K1 Angiogenesis
K1 Immunotherapy
K1 Monoclonal antibody
K1 Renal cell cancer
K1 Targeted therapy
K1 Tyrosine-kinase inhibitor
K1 mTOR inhibitor
AB Kidney cancer represents about 5% of all new cancer diagnoses. The most common form of kidney cancer arises from renal epithelium, named renal cell carcinoma (RCC). This entity comprises different histological and molecular subtypes. Unraveling the molecular biology and cytogenetic of RCC has enabled the development of several targeted agents that have improved treatment outcomes of these patients. This article reviews all the agents currently approved for the treatment of RCC, and discuss upcoming molecules. Mechanism of action, preclinical and clinical development and ongoing trials, are presented for each agent, providing a broad vision of the current state of targeted therapy in RCC and possible future developments.
YR 2017
FD 2017-09-01
LK http://hdl.handle.net/10668/11573
UL http://hdl.handle.net/10668/11573
LA en
DS RISalud
RD Apr 8, 2025